Merck, ARIAD Pharma release sarcoma drug trial results
Oral ridaforolimus, an investigational mTOR inhibitor, was granted a special protocol assessment (SPA) by the US Food and Drug Administration (FDA) for the SUCCEED trial. Ridaforolimus improved progression-free
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.